Vor Biopharma Inc. (NASDAQ:VOR) Receives $66.13 Average Target Price from Brokerages

Shares of Vor Biopharma Inc. (NASDAQ:VOR) have earned an average rating of “Moderate Buy” from the twelve analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $66.1250.

A number of research firms recently weighed in on VOR. JPMorgan Chase & Co. reduced their price objective on shares of Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, December 19th. Zacks Research raised Vor Biopharma from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. HC Wainwright reduced their price target on Vor Biopharma from $55.00 to $32.00 and set a “buy” rating on the stock in a report on Friday, November 14th. TD Cowen started coverage on Vor Biopharma in a report on Wednesday, December 17th. They set a “buy” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st.

Vor Biopharma Stock Up 0.8%

NASDAQ VOR opened at $13.31 on Friday. Vor Biopharma has a 52 week low of $2.62 and a 52 week high of $65.80. The firm has a market capitalization of $138.56 million, a price-to-earnings ratio of -0.03 and a beta of 2.02. The company has a fifty day moving average of $13.77 and a two-hundred day moving average of $23.04.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. lifted its holdings in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after buying an additional 58,247 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Vor Biopharma during the first quarter valued at approximately $140,000. XTX Topco Ltd purchased a new stake in shares of Vor Biopharma in the second quarter valued at approximately $66,000. Ariose Capital Management Ltd bought a new position in Vor Biopharma in the third quarter worth approximately $5,368,000. Finally, BNP Paribas Financial Markets grew its stake in Vor Biopharma by 497.3% in the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock worth $296,000 after purchasing an additional 5,058 shares in the last quarter. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).